Risk Assessment: Medical Engineering Technologies Ltd (03295099)

1. Risk Rating: MEDIUM

On standalone historical fundamentals, this company would rate LOW: 29 years of continuous trading, net assets grown roughly tenfold since 2013 funded entirely through retained profits, minimal leverage, and a clean compliance record. The MEDIUM rating is driven by post-acquisition structural changes: the company was acquired by the WMP Bidco group in 2022, the most recent accounts appear to be filed under the subsidiary audit exemption (reduced assurance), a large debtor balance of apparently non-trade character now dominates the balance sheet, and no financial data is available for the period after September 2022 despite accounts having been filed to September 2025. This rating reflects unverifiable current conditions rather than observed distress.

2. Key Concerns

a) Post-acquisition opacity and group structure. WMP Bidco Limited holds more than 75% of shares and voting rights with the right to appoint/remove directors. The 2022 accounting period was shortened to 273 days specifically to align with the ultimate parent, WMP Newco Limited — confirming a 2022 change of control. The accounts category is now "Audit Exemption Subsidiary," indicating reliance on the s479A group exemption, meaning the most recent filings are likely unaudited. Critically, the group's leverage position — common in Bidco/Newco acquisition structures — is not visible from this company's filings.

b) Material shift in balance sheet composition. Debtors increased from £50,864 (Dec 2021) to £1,610,075 (Sept 2022) — a 30-fold rise in nine months. The XBRL tagging of this balance as current financial instruments (rather than trade debtors) suggests an intercompany position, likely a loan to or within the new group. Meanwhile, creditors due within one year nearly quadrupled to £575,921 and cash fell from £1,120,791 to £711,066. If the debtor balance is an intra-group loan to a leveraged parent, its recoverability and the company's true standalone liquidity require verification.

c) Data gap and reporting quality. The available financial history ends at September 2022, yet accounts have been filed to September 2025 — a three-year blind spot on the company's current position. Additionally, the 2022 accounts disclose a prior period error relating to revenue cut-off and omitted deferred income liabilities (the note is truncated in the available extract). A prior period error disclosure, while not uncommon in small-company accounts, points to a weakness in financial controls that should be understood.

3. Positive Indicators

• Consistent organic growth: Net assets rose from £216,137 (2013) to £2,254,821 (Sept 2022) in an unbroken year-on-year sequence. Share capital has remained at £105 throughout, and the P&L reserve equals shareholders' funds — confirming growth was funded entirely by retained profits with no reliance on external capital.
• Strong standalone solvency and liquidity at the last visible date: Cash of £711,066 exceeds all creditors due within one year (£575,921); net current assets of £1,745,220 represent a current ratio of approximately 4.0x; there is no long-term debt. Tangible assets of £574,639 include land and buildings, indicating owned property backing.
• Clean compliance and governance record: No overdue accounts or confirmation statements; the 2022 accounts were audited by Hazlewoods LLP and included a going concern statement; no insolvency markers; no director disqualification records appear in the available data.
• Continuity and sector resilience: Incorporated in 1996 with continuous trading; legacy director Xxxxxx Xxxxxxxxname shown to subscribers has remained through the ownership transition. The business — laboratory testing services for the medical sector (SIC 72190) — serves recurring, regulation-driven demand, a historically defensive profile.
• Notable performance acceleration: The implied retained profit for the nine-month 2022 period (£626,656) exceeds the prior full-year figure (£242,454), suggesting strong trading into the acquisition — though this should be verified for non-recurring items.

4. Due Diligence Notes

1. Obtain the FY2023–FY2025 accounts (filed to 30 September 2025). The company's current solvency and liquidity cannot be assessed from available data; this is the single most important gap to close.
2. Identify the nature of the £1.61m debtor balance — counterparty, terms, security (if any), and whether any cash-sweep or intercompany financing arrangement exists post-acquisition.
3. Review the charges register at Companies House for security granted over company assets to group lenders — standard in acquisition structures but not visible in the provided data.
4. Review WMP Newco Limited and WMP Bidco Limited group accounts for group leverage, and confirm the parent guarantee supporting the s479A audit exemption.
5. Obtain the full prior period error note and any restated comparatives; assess the control environment that allowed deferred income liabilities to be omitted.
6. Verify the PSC register — the simultaneous listing of a corporate PSC at >75% and an individual (Xxxxxx Xxxxxxxxname shown to subscribers) at 50–75% is structurally ambiguous; clarify whether Turner's interest is direct or held via the WMP entities.
7. Review the director transition — Xxxxxx Xxxxxxxxname shown to subscribers's resignation (August 2026) and Xxxxxx Xxxxxxxxname shown to subscribers's appointment — including other directorships held and any conduct records.
8. Confirm regulatory accreditation (e.g., UKAS/ISO 17025 status) underpinning the testing business, as loss of accreditation would be the principal operational risk in this sector.
9. Note on data quality: the extracted "total assets" figures in the financial history reconcile to current assets only; the analysis above uses figures cross-checked against the filed balance sheet, which should be treated as authoritative.

Names of the people mentioned are shown to subscribers. See subscription